Why is there a large selling pressure

Not today, not tomorrow and not next week. Paul and Sam have to get along and since they hate each other I don’t know how they could make a deal. Unless thing changes I don’t see how they can work together. Hope I am wrong.
I am long with XMDC I will wait till the end.
Good luck.

I think XMDC will be too late with their technology. Just have a look at
http://www.mhtx.com/
Too bad...

Boomer.

If the BK is for good then why people are not selling I find this very confusing and weird

Restructures:
Date Old Symbol Old Shares New Symbol New Shares
2011-03-07 XMDC 1 XMDCQ 1
2007-09-26 SMMW 8334 XMDC 1
2006-02-28 PRRM 1 SMMW 1
2003-12-31 PRRF 500 PRRM 1
2002-06-26 RMGS 1 PRRF 1
2001-07-17 RMGG 1 RMGS 1

XMDCQ BID 0.001 ASK 0.0023

Thanks Sammy for the update but if it is true then hard luck to all of us we are done.

Back reality LOL.

Level2 .0095 - 20.00 I wish its true LOL.

Hemispherx Publishes New Data on Ampligen(R)'s Activity in Chronic Fatigue Syndrome (CFS)


2010-11-22 05:00 PT - News Release

PHILADELPHIA, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced the publication of a peer-reviewed article providing new data on Ampligen® [rintatolimod; poly(I)·poly(C12,U)], an experimental therapeutic in Phase III clinical testing, in the current issue of The Journal of Applied Research. The report is entitled "Cardiac Toxicity in Chronic Fatigue Syndrome (CFS): Results from a Randomized 40-Week Multicenter Double-Blind Placebo Control Trial of Rintatolimod". Findings include discussion of the sedentary lifestyle produced by extreme fatigue which is a significant risk factor for heart disease, a leading cause of death in patients with CFS. Thus, cardiac abnormalities, including abnormal electrocardiograms (EKGs), are common in CFS patients despite their relatively young age.

The AMP-516, Phase III FDA-authorized study in CFS evaluated the therapeutic effectiveness of Ampligen®, an experimental therapeutic, and included repeated measurements of the QT interval, a component of EKG testing. Prolongation of the EKG QT interval is a known risk factor in sudden cardiac death (Long QT Syndrome) due to the induction of fatal cardiac arrhythmias. A greater portion of the placebo patients were found to have a significant prolongation of the QT interval compared to patients who had received Ampligen® twice weekly. The prolonged QT interval in the placebo group was associated with continued use of certain concomitant medications, which are known to prolong the QT interval and used by CFS patients in an attempt to mitigate symptoms of the disease. In contrast, patients randomized to receive Ampligen were able to significantly reduce their dependency on these same medications.

Concomitant medications which increase the QT interval may carry a "black box" warning on their labels since prolonged QT intervals are associated with cardiac arrhythmias which may result in sudden death.

The AMP-516 study was one of the studies submitted to FDA in the Ampligen® NDA, which resulted in the previously-announced November 25, 2009 Complete Response Letter, in which FDA requested that additional data be generated and submitted on effectiveness measures and potential QT interval effects.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx' flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® represents experimental nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx' platform technology includes agents for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States. For more information please visit www.hemispherx.net.

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen® and Alferon® LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications.

CONTACT: Hemispherx Biopharma, Inc.
Company/Investor Contact:
Dianne Will
518-398-6222
ir@hemispherx.net

i am sorry guys but this is not an impressive website, it is more like amateur website.
No videos not enough informations to attract new investors.

do you feel confident with the mediation without details. Sorry but I am not.

I agree with you we need details of the mediation. I don't know why is he hiding the details.

Great news but low volume I was expecting much higher.

Xtend Medical Corporation (XMDC) Confirms Acquisition of the BioHarp Assets


2010-10-04 06:00 PT - News Release

SUN VALLEY, CA -- (MARKET WIRE) -- 10/04/10


XTend Medical Corporation (PINKSHEETS: XMDC), a company that specializes in delivering life-changing medical technology to healthcare organizations globally, has successfully acquired the BioHarp Assets from Mr. Sang M. Lee and U&I Bio-Tech, Inc., as provided in the Asset Purchase Agreement that the parties signed on December 9, 2009. XTend's representatives and Mr. Lee completed the acquisition last Thursday, September 30, 2010, through a mediation proceeding in the Delaware Chancery Court.

The company released the following statement, "We are delighted that the mediation last Thursday was successful. Through the assistance of our litigation counsel, Mr. John Holcomb of Knobbe, Martens, Olson & Bear, LLP and Mr. David Teklits of Morris, Nichols, Arsht & Tunnell LLP, along with the wisdom and guidance of the mediator, Master Sam Glasscock III of the Delaware Chancery Court, XTend has finally secured the BioHarp assets, including the BioHarp patents and other intellectual property. XTend now can move forward with its plans to manufacture and commercialize the BioHarp technology so that the company can capitalize on the healthcare, veterinary, and horticulture industries. The company is eager to make sales in Korea, Japan, China, and the U.S. as quickly as possible. Additionally, XTend will work to complete audited financials expeditiously in order to become a fully reporting company. The company anticipates being listed on a higher exchange within the first quarter of 2011. Finally, the company would like to thank its loyal shareholders for their patience while this BioHarp acquisition process has progressed. The company is confident in its future as a leader in the medical technology sector."

About XTend Medical

XTend Medical Corporation is a company that specializes in the sale, manufacturing, and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. The company is dedicated to insuring that the products and services that it offers to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. XTend's recent acquisition of the BioHarp medical device will assist the company in becoming known as a leader in the healthcare sector globally. For further information, please contact the company at info@bioharpunius.com or visit its website at www.bioharpunius.com.

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

CONTACT
XTend Medical Corporation
info@bioharpunius.com

Thanks for the update looks good so far

http://beta.barchart.com/opinions/XMDC

News on fridays usually not good news.

Is the stock HALTED no bid and no ask.

Still here with all my shares and waiting.

For sure sellers are slowing down now lets hope Paul and Lee resolve their conflicts and it will be a new beginning.

Most recent close prices:
Date Ex:Sym Open Hi Lo Close Chg Vol #Tr Bid Ask
2010-03-16 Q : XMDC 0.0079 0.0083 0.0062 0.0064 -0.0016 9,268,630 101 0.00 0.00
2010-03-15 Q : XMDC 0.0098 0.0099 0.0073 0.008 -0.0012 15,746,108 194 0.00 0.00
2010-03-12 Q : XMDC 0.0083 0.01 0.008 0.0092 +0.0018 33,494,535 361 0.00 0.00
2010-03-11 Q : XMDC 0.0061 0.0084 0.0046 0.0074 +0.0014 49,512,253 462 0.00 0.00
2010-03-10 Q : XMDC 0.004 0.0075 0.0032 0.006 -0.017 150,418,831 918 0.00 0.00

Volume is getting smaller and smaller every day.

JC8484 Good post EOM.

I dont agree with you that XMDC is 99% fraud simply because the AS is still the same no increase at 1B. The day we see the AS start to go up with volume then we all have to get out of this stock and then we can say it is a fraud.For now it is a wait and see hoping Paul will deliver.

What is going on was it it suppose to go flying very disappointed to see it diving what do you guys think?

bharveyalamos Thanks and I appreciate your reply.

Rain what do you think of IGNT?
TIA.

Sorry I thought the market close at 1pm. Any way the last hour will be interesting.

Now is the last trading hour of the year so it either heavy selling or heavy buying.
Happy new year to all of you and yours.

Merry Christmas to all of you and your families.

Then who is selling but Paul look at the PPS will hit 2 before end of day.

In my opinion this pink sheets sucks Paul is playing the game again selling shares pps goes to .0001 and then a big RS and keep repeating the same game.in my opinion its all BS. I own 2M shares and I am dumping them.

I think the lack of details of the transaction is the problem. Paul did not give any detail of how did he pay and how much did he pay for this transaction and that is why people are nervous.

big resistance at 0.06 it will take big volume to cross.

At one point I had my doubt but I am so happy now that the deal is closed so we can look forward for other deals and contracts to come. the future is very bright for XMDC.

XTend Medical Corporation (XMDC) Finalizes Asset Purchase With BioHarp, Korea


2009-12-09 08:30 ET - News Release

SUN VALLEY, CA -- (MARKET WIRE) -- 12/09/09


XTend Medical, (PINKSHEETS: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, today announced the company has completed and signed the asset purchase agreement with BioHarp, Korea.

The company released the following statement, "Mr. Lee, Mr. Friedman, and I are pleased to announce the completion of the asset purchase agreement between XTend Medical and BioHarp, Korea. The process took a little longer than anticipated but we're extremely excited to finalize this agreement and work together with Mr. Lee to begin the manufacturing, marketing, and sales of the BioHarp device. XTend Medical has an incredible asset that will insure the company's valuation moving forward. The device will, in our opinion, be known very soon as the premier medical diagnostic tool worldwide. We're thoroughly impressed with the team behind the BioHarp and are looking forward to a long lasting relationship. XTend Medical will move quickly to gain sales in Korea, China, Japan, and other countries that have expressed interest in the unit and to have a combined operation so our reach is global in nature. We anticipate the sales of the BioHarp to reach phenomenal numbers in the coming years," stated Mr. Paul D. Lisenby, CEO of XTend Medical.

Mr. Lee, CEO of BioHarp, Korea, added, "I am extremely excited about the future of the BioHarp. Our team, combined with the management of XTend Medical, will insure the company's success. We look forward to working closely with Mr. Lisenby and Mr. Friedman as we begin the manufacturing and sales process globally and deploy the BioHarp to health organizations throughout the world."

About XTend Medical

XTend Medical is a company that specializes in the manufacturing and distribution of the latest in telemedicine and telehealth solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their continued efforts in identifying global companies with true product potential in the healthcare industry puts them in an advantageous position to capitalize on a global basis. For further information, please contact them at info@bioharpunius.com

The new website can be located at www.bioharpunius.com

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.

CONTACT
info@bioharpunius.com

Good morning level 2 looks very good
Bid Orders
Timestamp MM id BidSz Bid Price
12-07 09:10 NITE 5,000 0.0465
12-04 16:00 HDSN 5,000 0.042
12-07 09:11 ETMM 5,000 0.042
12-04 11:42 VERT 5,000 0.041
12-04 09:24 DOMS 5,000 0.034
11-19 08:19 MAXM 5,000 0.032
11-23 09:49 LAFC 5,000 0.032
12-02 11:14 STXG 5,000 0.032
11-13 15:22 ABLE 5,000 0.03
11-25 09:43 PUMA 5,000 0.03
12-04 10:22 SSGI 5,000 0.03
11-18 12:15 SALI 5,000 0.025
12-04 11:43 VFIN 5,000 0.02
12-07 08:10 UBSS 0 U
12-07 08:30 AUTO 0 U
Ask Orders
Ask Price AskSz MM id Timestamp
0.054 5,000 HDSN 12-04 16:00
0.054 5,000 NITE 12-07 09:10
0.055 5,000 PUMA 11-25 09:43
0.055 5,000 STXG 12-02 11:14
0.06 5,000 VERT 12-04 11:42
0.06 5,000 VFIN 12-04 11:43
0.065 5,000 DOMS 12-04 09:24
0.065 5,000 ETMM 12-07 09:11
0.075 5,000 LAFC 11-23 09:49
0.085 5,000 MAXM 11-19 08:19
0.10 5,000 ABLE 11-13 15:22
0.10 5,000 SALI 11-18 12:15
0.16 5,000 SSGI 12-04 10:22
U 0 UBSS 12-07 08:10
U 0 AUTO 12-07 08:30

Hemispherx Biopharma Announces Investor Conference Call


2009-12-02 08:30 ET - News Release

PHILADELPHIA, Dec. 2, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announces an investor update by teleconference on Thursday, December 3, 2009 at 10:00am EST. The update will cover regulatory status of its platform technology (Ampligen(R), Alferon-N(R), Alferon(R) LDO), strategic partnering and other matters, followed by a Q and A period.

To access the conference call:



U.S. Callers: 800-348-5860
International Callers: 973-528-0008
Conference Entry Code: 27781
This call will be webcast via the Company's website at: http://www.hemispherx.net.

A digital replay of the call will be available until December 18th by calling:



U.S. Callers: 800-332-6854
International Callers: 973-528-0005
Conference Entry Code: 27781
About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(R) Oragens(R), and Alferon LDO. Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 50 patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the completion of the NDA filing process with Ampligen(R) and the receipt of a Complete Response Letter from the FDA do not imply that the Company will be able to successfully comply with any or all of the requirements requested in that Letter or that the product will ever be approved for commercial sale. In addition, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R), Alferon(R) LDO and Oragens(R)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.

CONTACT: Hemispherx Biopharma, Inc.
Company/Investor Contact:
Dianne Will
518-398-6222
ir@hemispherx.net

Cross my fingers and hope you are right.